{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T05:11:05Z","timestamp":1779167465466,"version":"3.51.4"},"reference-count":150,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Nasopharyngeal carcinoma (NPC) presents unique clinical and biological characteristics that distinguish it from other head and neck malignancies. It poses a great therapeutic challenge for many specialists. It is associated with Epstein\u2013Barr virus (EBV) infection, genetic predisposition, and environmental risk factors. With advancements in radiotherapy and systemic therapy, new treatment options have emerged. We want to focus on contemporary therapeutic strategies for NPC, emphasizing breakthroughs in intensity-modulated radiotherapy (IMRT), chemoradiotherapy, targeted therapy, immunotherapy, and emerging cellular therapies. By integrating recent discoveries with clinical evidence, we aim to provide state-of-the-art information, along with a comprehensive understanding of current best practices, emerging treatments, and critical prognostic determinants in NPC.<\/jats:p>","DOI":"10.3390\/life16050764","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T02:06:21Z","timestamp":1777860381000},"page":"764","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic Innovations in Nasopharyngeal Carcinoma: Current Strategies and Emerging Perspectives"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9616-0458","authenticated-orcid":false,"given":"Weronika","family":"Paj\u0105k","sequence":"first","affiliation":[{"name":"Department of Forensic Medicine, Medical University of Lublin, Jaczewskiego 8b, 20-090 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3742-5696","authenticated-orcid":false,"given":"Jakub","family":"Kleinrok","sequence":"additional","affiliation":[{"name":"Chair and Department of Clinical Pathomorphology, Medical University of Lublin, Jaczewskiego 8b, 20-090 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5525-7338","authenticated-orcid":false,"given":"Joanna","family":"Pec","sequence":"additional","affiliation":[{"name":"Department of Forensic Medicine, Medical University of Lublin, Jaczewskiego 8b, 20-090 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Orzechowski","sequence":"additional","affiliation":[{"name":"Department of Forensic Medicine, Medical University of Lublin, Jaczewskiego 8b, 20-090 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9779-3030","authenticated-orcid":false,"given":"Jakub","family":"Drabko","sequence":"additional","affiliation":[{"name":"Department of Forensic Medicine, Medical University of Lublin, Jaczewskiego 8b, 20-090 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryszard","family":"Sitarz","sequence":"additional","affiliation":[{"name":"1st Department of Psychiatry, Psychotherapy and Early Intervention, Medical University of Lublin, Gluska Street 1, 20-439 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8714-7627","authenticated-orcid":false,"given":"Alicja","family":"Forma","sequence":"additional","affiliation":[{"name":"Department of Forensic Medicine, Medical University of Lublin, Jaczewskiego 8b, 20-090 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7223-2500","authenticated-orcid":false,"given":"Adam","family":"Brachet","sequence":"additional","affiliation":[{"name":"Department of Correct, Clinical, and Imaging Anatomy, Medical University of Lublin, Jaczewskiego 4, 20-090 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1101-3566","authenticated-orcid":false,"given":"Barbara","family":"Teresi\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Correct, Clinical, and Imaging Anatomy, Medical University of Lublin, Jaczewskiego 4, 20-090 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1372-8987","authenticated-orcid":false,"given":"Jacek","family":"Baj","sequence":"additional","affiliation":[{"name":"Doctoral School, Medical University of Lublin, Chod\u017aki 7, 20-093 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.14639\/0392-100X-N2223","article-title":"Nasopharyngeal carcinoma. A \u201cdifferent\u201d head and neck tumour. Part B: Treatment, prognostic factors, and outcomes","volume":"43","year":"2023","journal-title":"Acta Otorhinolaryngol. Ital."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1097\/CM9.0000000000000978","article-title":"The evolution of the nasopharyngeal carcinoma staging system over a 10-year period: Implications for future revisions","volume":"133","author":"Tang","year":"2020","journal-title":"Chin. Med. J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e091087","DOI":"10.1136\/bmjopen-2024-091087","article-title":"Global epidemiological profile in nasopharyngeal carcinoma: A prediction study","volume":"14","author":"Zhang","year":"2024","journal-title":"BMJ Open"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1002\/lary.31939","article-title":"Global, Regional, and National Burden of Nasopharyngeal Carcinoma from 1990 to 2021","volume":"135","author":"Wu","year":"2025","journal-title":"Laryngoscope"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1007\/s00405-024-08500-8","article-title":"Salvage endoscopic nasopharyngectomy for recurrent nasopharyngeal carcinoma in a non-endemic area","volume":"281","author":"Valentini","year":"2024","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.14639\/0392-100X-suppl.1-45-2025-N1170","article-title":"Margins in oncologic nasopharyngeal surgery: A systematic review with meta-analysis","volume":"45","author":"Daloiso","year":"2025","journal-title":"Acta Otorhinolaryngol. Ital."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"101995","DOI":"10.1016\/j.ctrv.2020.101995","article-title":"Current management of stage IV nasopharyngeal carcinoma without distant metastasis","volume":"85","author":"Ng","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.oraloncology.2015.11.015","article-title":"Long-term patterns of relapse and survival following definitive intensity-modulated radiotherapy for non-endemic nasopharyngeal carcinoma","volume":"53","author":"Setton","year":"2016","journal-title":"Oral Oncol."},{"key":"ref_9","first-page":"814948","article-title":"Clinical outcomes and prognostic factors of 695 nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy","volume":"2014","author":"Wang","year":"2014","journal-title":"BioMed Res. Int."},{"key":"ref_10","first-page":"1419676","article-title":"A Study of 358 Cases of Locally Advanced Nasopharyngeal Carcinoma Receiving Intensity-Modulated Radiation Therapy: Improving the Seventh Edition of the American Joint Committee on Cancer T-Staging System","volume":"2017","author":"Zhou","year":"2017","journal-title":"BioMed Res. Int."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3906\/sag-1605-98","article-title":"The results of nasopharyngeal cancer patients treated by simultaneous integrated boost technique and concomitant chemotherapy","volume":"49","author":"Karabekir","year":"2019","journal-title":"Turk. J. Med. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1001\/jama.2023.20181","article-title":"Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial","volume":"330","author":"Mai","year":"2023","journal-title":"JAMA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1080\/00016489.2022.2111711","article-title":"The global, regional, and national burden of nasopharyngeal carcinoma and its attributable risk factors in 204 countries and territories, 1990\u20132019","volume":"142","author":"Zhang","year":"2022","journal-title":"Acta Otolaryngol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e71183","DOI":"10.1096\/fj.202502319RR","article-title":"EBV-LMP1 Promotes the Progression of Nasopharyngeal Carcinoma via TNC-Mediated Activation of PI3K\/Akt Pathway","volume":"39","author":"Zhang","year":"2025","journal-title":"FASEB J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1186\/s12985-025-02973-7","article-title":"An automatic NGS feature extraction algorithm for predicting EBV-associated nasopharyngeal cancer and high-risk mutation","volume":"22","author":"Wang","year":"2025","journal-title":"Virol. J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.31557\/APJCP.2019.20.11.3505","article-title":"Nasopharyngeal Carcinoma (NPC) Risk Factors: A Systematic Review and Meta-Analysis of the Association with Lifestyle, Diets, Socioeconomic and Sociodemographic in Asian Region","volume":"20","author":"Okekpa","year":"2019","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.31557\/APJCP.2023.24.4.1105","article-title":"Risk Factors Associated with Nasopharyngeal Cancer Incidences in Indonesia: A Systematic Review and Meta-Analysis","volume":"24","author":"Romdhoni","year":"2023","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1073274820944286","DOI":"10.1177\/1073274820944286","article-title":"Validation of a Highly Sensitive qPCR Assay for the Detection of Plasma Cell-Free Epstein-Barr Virus DNA in Nasopharyngeal Carcinoma Diagnosis","volume":"27","author":"Anh","year":"2020","journal-title":"Cancer Control"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1479-5876-10-57","article-title":"Further evidence for the existence of major susceptibility of nasopharyngeal carcinoma in the region near HLA-A locus in Southern Chinese","volume":"10","author":"Zhao","year":"2012","journal-title":"J. Transl. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.humimm.2010.10.006","article-title":"Association of HLA-G polymorphisms with nasopharyngeal carcinoma risk and clinical outcome","volume":"72","author":"Ghandri","year":"2011","journal-title":"Hum. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1002\/cncr.30643","article-title":"Quantification of familial risk of nasopharyngeal carcinoma in a high-incidence area","volume":"123","author":"Liu","year":"2017","journal-title":"Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s00405-021-06922-2","article-title":"The global burden of nasopharyngeal carcinoma from 2009 to 2019: An observational study based on the Global Burden of Disease Study 2019","volume":"279","author":"Yu","year":"2022","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Jia, W.H., Luo, X.Y., Feng, B.J., Ruan, H.L., Bei, J.X., Liu, W.S., Qin, H.D., Feng, Q.S., Chen, L.Z., and Yao, S.Y. (2010). Traditional Cantonese diet and nasopharyngeal carcinoma risk: A large-scale case-control study in Guangdong, China. BMC Cancer, 10.","DOI":"10.1186\/1471-2407-10-446"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Lyu, Y.H., Lin, C.Y., Xie, S.H., Li, T., Liu, Q., Ling, W., Lu, Y.Q., Cao, S.M., and Lin, A.H. (2021). Association Between Traditional Herbal Diet and Nasopharyngeal Carcinoma Risk: A Prospective Cohort Study in Southern China. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.715242"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Lo, Y.L., Pan, W.H., Hsu, W.L., Chien, Y.C., Chen, J.Y., Hsu, M.M., Lou, P.J., Chen, I.H., Hildesheim, A., and Chen, C.J. (2016). Partial Least Square Discriminant Analysis Discovered a Dietary Pattern Inversely Associated with Nasopharyngeal Carcinoma Risk. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0155892"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1002\/cam4.2832","article-title":"Cigarette smoking increases the risk of nasopharyngeal carcinoma through the elevated level of IgA antibody against Epstein-Barr virus capsid antigen: A mediation analysis","volume":"9","author":"Hsu","year":"2020","journal-title":"Cancer Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/aje\/kws479","article-title":"Quantitative association of tobacco smoking with the risk of nasopharyngeal carcinoma: A comprehensive meta-analysis of studies conducted between 1979 and 2011","volume":"178","author":"Xue","year":"2013","journal-title":"Am. J. Epidemiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1158\/1055-9965.EPI-13-0546","article-title":"Prognostic impact of cigarette smoking on the survival of patients with established nasopharyngeal carcinoma","volume":"22","author":"Ouyang","year":"2013","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.envres.2018.12.022","article-title":"Occupational exposure to wood dust and risk of nasopharyngeal cancer: A systematic review and meta-analysis","volume":"171","author":"Beigzadeh","year":"2019","journal-title":"Environ. Res."},{"key":"ref_30","unstructured":"Kumar, V., Abbas, A.K., Aster, J.C., Debnath, J., and Das, A. (2025). Robbins, Cotran & Kumar Pathologic Basis of Disease, Elsevier. [11th ed.]."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s12105-022-01449-2","article-title":"Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Oropharynx and Nasopharynx","volume":"16","author":"Badoual","year":"2022","journal-title":"Head Neck Pathol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1053\/j.semdp.2015.02.021","article-title":"Nasopharyngeal carcinoma: A review","volume":"32","author":"Petersson","year":"2015","journal-title":"Semin. Diagn. Pathol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Marin, M.A., Closca, R.-M., Marin, A., Rakitovan, M., Nicoara, A., Poenaru, M., Militaru, M., and Baderca, F. (2024). Clinical, Epidemiological, Morphological, and Immunohistochemical Aspects of Nasopharyngeal Carcinoma\u20144-Year Retrospective Study in the Western Part of Romania. Diagnostics, 14.","DOI":"10.3390\/diagnostics14070722"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-023-01928-2","article-title":"Nasopharyngeal carcinoma: Current views on the tumor microenvironment\u2019s impact on drug resistance and clinical outcomes","volume":"23","author":"Liu","year":"2024","journal-title":"Mol. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1001\/jamaoncol.2024.4354","article-title":"Ninth Version of the AJCC and UICC Nasopharyngeal Cancer TNM Staging Classification","volume":"10","author":"Pan","year":"2024","journal-title":"JAMA Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3348\/jksr.2025.0118","article-title":"Recent AJCC Version 9 Staging of Nasopharyngeal Cancer","volume":"87","author":"Lee","year":"2026","journal-title":"J. Korean Soc. Radiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1748-717X-3-4","article-title":"Intensity-modulated radiotherapy of nasopharyngeal carcinoma: A comparative treatment planning study of photons and protons","volume":"3","author":"Nill","year":"2008","journal-title":"Radiat. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ijrobp.2008.05.065","article-title":"Intensity-modulated proton therapy versus helical tomotherapy in nasopharynx cancer: Planning comparison and NTCP evaluation","volume":"72","author":"Widesott","year":"2008","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"E1886","DOI":"10.1002\/hed.24341","article-title":"Intensity-modulated proton therapy for nasopharyngeal carcinoma: Decreased radiation dose to normal structures and encouraging clinical outcomes","volume":"38","author":"Lewis","year":"2016","journal-title":"Head Neck"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0167-8140(01)00403-0","article-title":"A treatment planning comparison of 3D conformal therapy, intensity modulated photon therapy and proton therapy for treatment of advanced head and neck tumours","volume":"61","author":"Cozzi","year":"2001","journal-title":"Radiother. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"5574","DOI":"10.1200\/jco.2004.22.90140.5574","article-title":"Proton radiotherapy for T4 nasopharyngeal carcinoma","volume":"22","author":"Chan","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"S151","DOI":"10.1016\/j.ijrobp.2012.07.391","article-title":"A phase II trial of proton radiation therapy with chemotherapy for nasopharyngeal carcinoma","volume":"84","author":"Chan","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_43","unstructured":"Particle Therapy Co-Operative Group (2026, April 14). Facilities in Operation (Public). Available online: https:\/\/www.ptcog.site\/index.php\/facilities-in-operation-public."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Chen, Y.H., Blommestein, H.M., Klazenga, R., Uyl-de Groot, C., and van Vulpen, M. (2023). Costs of Newly Funded Proton Therapy Using Time-Driven Activity-Based Costing in The Netherlands. Cancers, 15.","DOI":"10.3390\/cancers15020516"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1016\/j.ijrobp.2012.09.033","article-title":"Replanning during intensity modulated radiation therapy improved quality of life in patients with nasopharyngeal carcinoma","volume":"85","author":"Yang","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/hed.23477","article-title":"Clinical outcomes among patients with head and neck cancer treated by intensity-modulated radiotherapy with and without adaptive replanning","volume":"36","author":"Chen","year":"2014","journal-title":"Head Neck"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ijrobp.2010.03.014","article-title":"Adaptive planning in intensity-modulated radiation therapy for head and neck cancers: Single-institution experience and clinical implications","volume":"80","author":"Ahn","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.radonc.2012.10.010","article-title":"Adaptive radiotherapy for head and neck cancer\u2014Dosimetric results from a prospective clinical trial","volume":"106","author":"Schwartz","year":"2013","journal-title":"Radiother. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/ajco.12516","article-title":"Head and neck adaptive radiotherapy: Predicting the time to replan","volume":"12","author":"Brown","year":"2016","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"105203","DOI":"10.1016\/j.ejmp.2025.105203","article-title":"Timing or criteria to trigger adaptive radiotherapy (ART) for nasopharyngeal carcinoma (NPC): A systematic review","volume":"139","author":"Wong","year":"2025","journal-title":"Phys. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.1998.16.4.1310","article-title":"Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099","volume":"16","author":"LeBlanc","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"6730","DOI":"10.1200\/JCO.2005.16.790","article-title":"Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer\/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety","volume":"23","author":"Wee","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1200\/JCO.22.00327","article-title":"Final Overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: A Multicenter, Randomized Phase III Trial","volume":"40","author":"Zhang","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"6966","DOI":"10.1200\/JCO.2004.00.7542","article-title":"Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group","volume":"23","author":"Lee","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1093\/jnci\/dji084","article-title":"Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma","volume":"97","author":"Chan","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.2002.08.149","article-title":"Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: Progression-free survival analysis of a phase III randomized trial","volume":"20","author":"Chan","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.ijrobp.2007.12.028","article-title":"Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of China","volume":"71","author":"Chen","year":"2008","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Zhao, X., Tian, L., Chen, Y., Yang, Q., Xie, T., Chen, M., Rao, J., Yang, M., Huang, N., and Ren, Y. (2024). Long-term outcomes of induction chemotherapy followed by concurrent chemoradiotherapy and adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: A retrospective study. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1475176"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"6148","DOI":"10.1182\/blood-2009-02-203687","article-title":"Discerning regulation of cis- and trans-presentation of CD8+ T-cell epitopes by EBV-encoded oncogene LMP-1 through self-aggregation","volume":"113","author":"Smith","year":"2009","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1084\/jem.191.10.1649","article-title":"Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1","volume":"191","author":"Bickham","year":"2000","journal-title":"J. Exp. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ctrv.2018.02.008","article-title":"Immunotherapy in head and neck cancers: A new challenge for immunologists, pathologists and clinicians","volume":"65","author":"Alt","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"111094","DOI":"10.1016\/j.intimp.2023.111094","article-title":"Combinations of radiotherapy with immunotherapy in nasopharyngeal carcinoma","volume":"125","author":"Yang","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1158\/1078-0432.CCR-21-3351","article-title":"Phase II clinical trial of neoadjuvant and adjuvant pembrolizumab in resectable local\u2013regionally advanced head and neck squamous cell carcinoma","volume":"28","author":"Gulati","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s00262-024-03905-0","article-title":"Metastatic sites of baseline as predictors in recurrent or metastatic nasopharyngeal carinoma treated with PD-L1 inhibitor: A secondary analysis of multicenter, single-arm, phase II study (KL-A167)","volume":"74","author":"Li","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1016\/S0140-6736(24)00594-4","article-title":"Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): A multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial","volume":"403","author":"Liu","year":"2024","journal-title":"Lancet"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1038\/bjc.2017.357","article-title":"Systemic therapies for recurrent or metastatic nasopharyngeal carcinoma: A systematic review","volume":"117","author":"Prawira","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"oyaf175","DOI":"10.1093\/oncolo\/oyaf175","article-title":"Indirect comparison of TPF and GP induction chemotherapy regimens in nasopharyngeal carcinoma: A data-driven reassessment before the transition to induction chemoimmunotherapy","volume":"30","author":"Cavalieri","year":"2025","journal-title":"Oncologist"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Zhu, Y., and Xue, F. (2024). Comparing long-term efficacy and safety of GP versus TPF sequential chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A propensity score-matched analysis. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-12932-0"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"17588359251413429","DOI":"10.1177\/17588359251413429","article-title":"Comparing three induction regimens for nasopharyngeal carcinoma: A propensity score-matched analysis","volume":"18","author":"Dai","year":"2026","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Guo, L.F., Yu, Y.F., Lu, Z.Z., Lin, Q., and Wu, S.G. (2025). Two or three cycles of induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma?. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-14699-4"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejca.2019.07.007","article-title":"Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: Long-term results of a phase III multicentre randomised controlled trial","volume":"119","author":"Yang","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1200\/JCO.2017.74.9457","article-title":"Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial","volume":"36","author":"Noronha","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/S1470-2045(16)30410-7","article-title":"Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicentre, randomised controlled trial","volume":"17","author":"Sun","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e41278","DOI":"10.1097\/MD.0000000000041278","article-title":"Comparison of TPF and PF induction chemotherapy combined with cisplatin concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A systematic review and meta-analysis","volume":"104","author":"Li","year":"2025","journal-title":"Medicine"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Yang, S.-S., Guo, J.-G., Liu, J.-N., Liu, Z.-Q., Chen, E.-N., Chen, C.-Y., Ouyang, P.-Y., Han, F., and Xie, F.-Y. (2021). Effect of Induction Chemotherapy in Nasopharyngeal Carcinoma: An Updated Meta-Analysis. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.591205"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"101625","DOI":"10.1016\/j.eclinm.2022.101625","article-title":"Induction chemotherapy regimen of docetaxel plus cisplatin versus docetaxel, cisplatin plus fluorouracil followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: Preliminary results of an open-label, noninferiority, multicentre, randomised, controlled phase 3 trial","volume":"53","author":"Wang","year":"2022","journal-title":"EClinicalMedicine"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(21)00075-9","article-title":"Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: An open-label, non-inferiority, randomised, controlled, phase 3 trial","volume":"22","author":"Lv","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.4143\/crt.2022.1651","article-title":"Individualized Concurrent Chemotherapy for Patients with Stage III-IVa Nasopharyngeal Carcinoma Receiving Neoadjuvant Chemotherapy Combined with Definitive Intensity-Modulated Radiotherapy","volume":"55","author":"Ji","year":"2023","journal-title":"Cancer Res. Treat."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Zhang, W., Meng, Y., Zhang, P., Tian, D., Zeng, X., Dong, M., and He, L. (2025). PD-1 inhibitor combined with TPF induction chemotherapy in locally advanced nasopharyngeal carcinoma: A retrospective study of efficacy and safety. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1654616"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Liu, X., Shang, Z., Gao, J., Jiang, N., Wang, J., Zhou, D., and Gui, Y. (2025). PD-1\/PD-L1 inhibitors for locally advanced nasopharyngeal carcinoma: A systematic review and meta-analysis based on randomized controlled trials. BMC Cancer, 26.","DOI":"10.1186\/s12885-025-15229-y"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e70825","DOI":"10.1002\/jmv.70825","article-title":"Epstein-Barr Virus Infection at Single-Cell Resolution","volume":"98","author":"SoRelle","year":"2026","journal-title":"J. Med. Virol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41420-026-02999-y","article-title":"Harnessing the immune microenvironment: Advances in nasopharyngeal carcinoma immunotherapy","volume":"12","author":"Zhu","year":"2026","journal-title":"Cell Death Discov."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.semcancer.2018.01.008","article-title":"Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments","volume":"52","author":"Solomon","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Nair, S., Bonner, J.A., and Bredel, M. (2022). EGFR Mutations in Head and Neck Squamous Cell Carcinoma. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23073818"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12967-024-05880-7","article-title":"Unveiling immune resistance mechanisms in nasopharyngeal carcinoma and emerging targets for antitumor immune response: Tertiary lymphoid structures","volume":"23","author":"Wang","year":"2025","journal-title":"J. Transl. Med."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Liao, L.J., Hsu, W.L., Chen, C.J., and Chiu, Y.L. (2023). Feature Reviews of the Molecular Mechanisms of Nasopharyngeal Carcinoma. Biomedicines, 11.","DOI":"10.3390\/biomedicines11061528"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1007\/s10565-023-09830-9","article-title":"Targeting the crosstalk of epigenetic modifications and immune evasion in nasopharyngeal cancer","volume":"39","author":"Looi","year":"2023","journal-title":"Cell Biol. Toxicol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3892\/or.2026.9082","article-title":"Advances in immunotherapy and targeted therapy for nasopharyngeal carcinoma: Current progress and combined approaches (Review)","volume":"55","author":"Yang","year":"2026","journal-title":"Oncol. Rep."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1007\/s12672-025-04049-y","article-title":"Efficacy and safety of PD-1 inhibitors combined with anti-angiogenic agents in patients with recurrent or metastatic nasopharyngeal carcinoma: A systematic review and meta-analysis","volume":"16","author":"Gao","year":"2025","journal-title":"Discov. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3892\/ijo.2023.5545","article-title":"Immunotherapy for nasopharyngeal carcinoma: Current status and prospects (Review)","volume":"63","author":"Huang","year":"2023","journal-title":"Int. J. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"102200","DOI":"10.1016\/j.xcrm.2025.102200","article-title":"Interferon-responsive HEVs drive tumor tertiary lymphoid structure formation and predict immunotherapy response in nasopharyngeal carcinoma","volume":"6","author":"Liu","year":"2025","journal-title":"Cell Rep. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"102840","DOI":"10.1016\/j.ctrv.2024.102840","article-title":"Advances and challenges in immunotherapy for locally advanced nasopharyngeal carcinoma","volume":"131","author":"Cai","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Luo, J., Xiao, W., Hua, F., Cao, Y., Wang, D., and Wang, X. (2023). Efficacy and safety of PD-1 inhibitors in recurrent or metastatic nasopharyngeal carcinoma patients after failure of platinum-containing regimens: A systematic review and meta-analysis. BMC Cancer, 23.","DOI":"10.1186\/s12885-023-11318-y"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Jia, H., Wang, J., Zhang, L., Li, H., Du, Y., Luo, W., Wei, Z., Wang, X., and Wang, W. (2025). Short-course PD-1 blockade in locally advanced nasopharyngeal carcinoma: A phase II randomized trial protocol (Tori-013). Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1633243"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2147\/CMAR.S460716","article-title":"Efficacy and Safety of Re-Challenging PD-1 Inhibitors in Second-Line Treatment in Metastatic Nasopharyngeal Carcinoma Previously Treated with Chemotherapy and PD-1 Inhibitors","volume":"16","author":"Bei","year":"2024","journal-title":"Cancer Manag. Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e472460","DOI":"10.1200\/EDBK-25-472460","article-title":"Updates on Treatments and Management of Nasopharyngeal Carcinoma","volume":"45","author":"Chua","year":"2025","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Xu, R., Wong, C.H.L., Chan, K.S.K., and Chiang, C.L. (2024). PD-L1 expression as a potential predictor of immune checkpoint inhibitor efficacy and survival in patients with recurrent or metastatic nasopharyngeal cancer: A systematic review and meta-analysis of prospective trials. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1386381"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1001\/jama.2025.1132","article-title":"Adjuvant PD-1 Blockade with Camrelizumab for Nasopharyngeal Carcinoma: The DIPPER Randomized Clinical Trial","volume":"333","author":"Liang","year":"2025","journal-title":"JAMA"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e47828","DOI":"10.1097\/MD.0000000000047828","article-title":"PD-1\/PD-L1 inhibitors in recurrent or metastatic nasopharyngeal carcinoma: A systematic review and meta-analysis","volume":"105","author":"Bai","year":"2026","journal-title":"Medicine"},{"key":"ref_100","first-page":"191","article-title":"The Relationship between Tumor-infiltrating Lymphocytes (TILs) and Nasopharyngeal Carcinoma (NPC): A Systematic Review","volume":"33","author":"Prasetyo","year":"2021","journal-title":"Iran. J. Otorhinolaryngol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"101885","DOI":"10.1016\/j.tranon.2024.101885","article-title":"The role of tertiary lymphoid structure and B cells in nasopharyngeal carcinoma: Based on bioinformatics and experimental verification","volume":"41","author":"Chen","year":"2024","journal-title":"Transl. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1089\/vim.2023.0118","article-title":"Epstein-Barr Virus BRLF1 Induces PD-L1 Expression in Nasopharyngeal Carcinoma Cells","volume":"37","author":"Wu","year":"2024","journal-title":"Viral Immunol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"12189","DOI":"10.18632\/oncotarget.2608","article-title":"EBV-driven LMP1 and IFN-\u03b3 up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy","volume":"5","author":"Fang","year":"2014","journal-title":"Oncotarget"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"106083","DOI":"10.1016\/j.oraloncology.2022.106083","article-title":"Vaccination as a therapeutic strategy for Nasopharyngeal carcinoma","volume":"135","author":"Huang","year":"2022","journal-title":"Oral Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Kim, J., Lee, Y., Kim, S., and Park, J.C. (2025). Novel Therapeutic Development for Nasopharyngeal Carcinoma. Curr. Oncol., 32.","DOI":"10.3390\/curroncol32090479"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/CJI.0b013e3181f3cbf4","article-title":"Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma","volume":"33","author":"Louis","year":"2010","journal-title":"J. Immunother."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Li, S., Dai, W., Kam, N.-W., Zhang, J., Lee, V.H.F., Ren, X., and Kwong, D.L.-W. (2024). The Role of Natural Killer Cells in the Tumor Immune Microenvironment of EBV-Associated Nasopharyngeal Carcinoma. Cancers, 16.","DOI":"10.3390\/cancers16071312"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"18","DOI":"10.21037\/cco.2016.03.07","article-title":"Clinical utility of circulating Epstein-Barr virus DNA analysis for the management of nasopharyngeal carcinoma","volume":"5","author":"Fung","year":"2016","journal-title":"Chin. Clin. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Zhu, L., Ouyang, T., Xiong, Y., Ba, L., Li, Q., Qiu, M., Zou, Z., and Peng, G. (2021). Prognostic Value of Plasma Epstein-Barr Virus DNA Levels Pre- and Post-Neoadjuvant Chemotherapy in Patients with Nasopharyngeal Carcinoma. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.714433"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.ijrobp.2017.03.018","article-title":"Clinical Utility of Epstein-Barr Virus DNA Testing in the Treatment of Nasopharyngeal Carcinoma Patients","volume":"98","author":"Kim","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"106655","DOI":"10.1016\/j.oraloncology.2023.106655","article-title":"Longitudinal post-radiotherapy plasma Epstein-Barr virus DNA trends inform on optimal risk stratification in endemic nasopharyngeal carcinoma","volume":"148","author":"Neo","year":"2024","journal-title":"Oral Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"115396","DOI":"10.1016\/j.ejca.2025.115396","article-title":"Plasma Epstein-Barr virus DNA for disease surveillance in endemic nasopharyngeal carcinoma: Analysis of a real-world database","volume":"220","author":"Neo","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2478\/raon-2018-0016","article-title":"Prognostic Value of Plasma EBV DNA for Nasopharyngeal Cancer Patients during Treatment with Intensity-modulated Radiation Therapy and Concurrent Chemotherapy","volume":"52","author":"Lertbutsayanukul","year":"2018","journal-title":"Radiol. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/s41416-018-0026-9","article-title":"Prospective evaluation of plasma Epstein-Barr virus DNA clearance and fluorodeoxyglucose positron emission scan in assessing early response to chemotherapy in patients with advanced or recurrent nasopharyngeal carcinoma","volume":"118","author":"Ma","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/jmv.27440","article-title":"Cell-free EBV DNA as a biomarker during clinical management of nasopharyngeal carcinoma in a nonendemic region","volume":"94","author":"Pramanik","year":"2022","journal-title":"J. Med. Virol."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Chen, W.J., Xu, W.N., Wang, H.Y., Chen, X.X., Li, X.Q., Xie, S.H., Lin, D.F., and Cao, S.M. (2021). Plasma Epstein-Barr virus DNA and risk of nasopharyngeal carcinoma in a prospective seropositive population. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08408-0"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1001\/jamaoncol.2020.6154","article-title":"Treatment Deescalation Strategies for Nasopharyngeal Cancer: A Review","volume":"7","author":"Lee","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ejca.2021.05.022","article-title":"A systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma","volume":"153","author":"Lee","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"100748","DOI":"10.1016\/j.bj.2024.100748","article-title":"Molecular diagnosis of nasopharyngeal carcinoma: Past and future","volume":"48","author":"Hsu","year":"2025","journal-title":"Biomed. J."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Liu, X., Li, Y., Zhou, X., Zhu, S., Kaya, N.A., Chan, Y.S., Ma, L., Xu, M., and Zhai, W. (2023). An Integrative Analysis of Nasopharyngeal Carcinoma Genomes Unraveled Unique Processes Driving a Viral-Positive Cancer. Cancers, 15.","DOI":"10.3390\/cancers15041243"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/s41422-020-0374-x","article-title":"Single-cell transcriptomics reveals regulators underlying immune cell diversity and immune subtypes associated with prognosis in nasopharyngeal carcinoma","volume":"30","author":"Chen","year":"2020","journal-title":"Cell Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"7713","DOI":"10.1038\/s41467-024-52153-4","article-title":"Single-cell and spatial transcriptome analyses reveal tertiary lymphoid structures linked to tumour progression and immunotherapy response in nasopharyngeal carcinoma","volume":"15","author":"Liu","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e70061","DOI":"10.1002\/ctm2.70061","article-title":"Single-cell transcriptome analysis reveals evolving tumour microenvironment induced by immunochemotherapy in nasopharyngeal carcinoma","volume":"14","author":"Jiang","year":"2024","journal-title":"Clin. Transl. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2242577","DOI":"10.1155\/2023\/2242577","article-title":"Nasopharyngeal Carcinoma Subtype Discovery via Immune Cell Scores from Tumor Microenvironment","volume":"2023","author":"Sun","year":"2023","journal-title":"J. Immunol. Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/cac2.12100","article-title":"Clinical utility of Epstein-Barr virus DNA and other liquid biopsy markers in nasopharyngeal carcinoma","volume":"40","author":"Tan","year":"2020","journal-title":"Cancer Commun."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"e251196","DOI":"10.1136\/bcr-2022-251196","article-title":"Use of circulating tumour DNA in nasopharyngeal carcinoma to detect minimal residual disease","volume":"15","author":"Ghimire","year":"2022","journal-title":"BMJ Case Rep."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"105321","DOI":"10.1016\/j.ebiom.2024.105321","article-title":"Establishment and validation of circulating cell-free DNA signatures for nasopharyngeal carcinoma detection","volume":"108","author":"Qiu","year":"2024","journal-title":"EBioMedicine"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"22086","DOI":"10.1038\/s41598-023-45001-w","article-title":"Blood-based DNA methylation in advanced Nasopharyngeal Carcinoma exhibited distinct CpG methylation signature","volume":"13","author":"Chatterjee","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_129","first-page":"2508","article-title":"The emerging roles of exosomal miRNAs in nasopharyngeal carcinoma","volume":"11","author":"Liao","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Shaw, P., Senthilnathan, R., Krishnan, S., Suresh, D., Shetty, S., Muthukaliannan, G.K., Mani, R.R., Sivanandy, P., Chandramoorthy, H.C.K., and Gupta, M.M. (2021). A Clinical Update on the Prognostic Effect of microRNA Biomarkers for Survival Outcome in Nasopharyngeal Carcinoma: A Systematic Review and Meta-Analysis. Cancers, 13.","DOI":"10.3390\/cancers13174369"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1200\/JCO-25-02111","article-title":"Development of a Classifier for Metabolic Subtypes of Nasopharyngeal Carcinoma to Guide Personalized Immunotherapy Strategies: Biomarker Analysis of the Phase III CONTINUUM and DIPPER Trials","volume":"44","author":"Huang","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Li, H., Kong, Z., Xiang, Y., Zheng, R., and Liu, S. (2022). The role of PET\/CT in radiotherapy for nasopharyngeal carcinoma. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1017758"},{"key":"ref_133","unstructured":"National Comprehensive Cancer Network (NCCN) (2026, March 04). NCCN Guidelines for Patients\u00ae: Nasopharyngeal Cancer. Plymouth Meeting (PA): National Comprehensive Cancer Network. Available online: https:\/\/d17k4s9qki18rb.cloudfront.net\/media\/uploads\/ORO\/hn-nasopharynx-patient.pdf."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"e39302","DOI":"10.1097\/MD.0000000000039302","article-title":"A systematic review of the predictive value of radiomics for nasopharyngeal carcinoma prognosis","volume":"103","author":"Deng","year":"2024","journal-title":"Medicine"},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Shen, H., Wang, Y., Liu, D., Lv, R., Huang, Y., Peng, C., Jiang, S., Wang, Y., He, Y., and Lan, X. (2020). Predicting Progression-Free Survival Using MRI-Based Radiomics for Patients with Nonmetastatic Nasopharyngeal Carcinoma. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00618"},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Wang, C.K., Wang, T.W., Lu, C.F., Wu, Y.T., and Hua, M.W. (2024). Deciphering the Prognostic Efficacy of MRI Radiomics in Nasopharyngeal Carcinoma: A Comprehensive Meta-Analysis. Diagnostics, 14.","DOI":"10.37766\/inplasy2024.2.0101"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"6677","DOI":"10.1007\/s00330-023-09606-z","article-title":"Multimodality radiomics analysis based on [18F]FDG PET\/CT imaging and multisequence MRI: Application to nasopharyngeal carcinoma prognosis","volume":"33","author":"Xu","year":"2023","journal-title":"Eur. Radiol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/s41746-025-02247-0","article-title":"Deep learning-based non-contrast MRI model for nasopharyngeal carcinoma diagnosis: An end-to-end gadolinium-free solution","volume":"8","author":"Li","year":"2025","journal-title":"npj Digit. Med."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Wang, C.K., Wang, T.W., Yang, Y.X., and Wu, Y.T. (2024). Deep Learning for Nasopharyngeal Carcinoma Segmentation in Magnetic Resonance Imaging: A Systematic Review and Meta-Analysis. Bioengineering, 11.","DOI":"10.37766\/inplasy2024.3.0120"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.ijrobp.2024.11.096","article-title":"Artificial Intelligence-Empowered Multistep Integrated Radiation Therapy Workflow for Nasopharyngeal Carcinoma","volume":"122","author":"Yang","year":"2025","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"e200029","DOI":"10.1148\/ryai.2020200029","article-title":"Checklist for artificial intelligence in medical imaging (CLAIM): A guide for authors and reviewers","volume":"2","author":"Mongan","year":"2020","journal-title":"Radiol. Artif. Intell."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1097\/CCM.0000000000006359","article-title":"The impact of multi-institution datasets on the generalizability of machine learning prediction models in the ICU","volume":"52","author":"Rockenschaub","year":"2024","journal-title":"Crit. Care Med."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"109744","DOI":"10.1016\/j.ejrad.2021.109744","article-title":"MRI based radiomics in nasopharyngeal cancer: Systematic review and perspectives using radiomic quality score (RQS) assessment","volume":"140","author":"Spadarella","year":"2021","journal-title":"Eur. J. Radiol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1148\/radiol.2020191145","article-title":"The Image Biomarker Standardization Initiative: Standardized quantitative radiomics for high-throughput image-based phenotyping","volume":"295","author":"Zwanenburg","year":"2020","journal-title":"Radiology"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"17588359221096214","DOI":"10.1177\/17588359221096214","article-title":"Current status and advances of immunotherapy in nasopharyngeal carcinoma","volume":"14","author":"Xu","year":"2022","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Liang, R., Lei, L., Li, X., Lan, F., Fu, F., Zou, T., Ma, L., Chen, P., Wang, Z., and Jin, J. (2025). Toripalimab plus gemcitabine and cisplatin induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: A retrospective study. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1704442"},{"key":"ref_147","first-page":"101547","article-title":"Immunotherapy in nasopharyngeal carcinoma: Current status and unanswered questions","volume":"57","author":"Liu","year":"2025","journal-title":"Lancet Reg. Health West. Pac."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s00405-024-08957-7","article-title":"Clinical features, operative management and surgical results of first Draf III procedure, revision Draf III approach and the use of mucosal flaps and stents: A systematic review","volume":"282","author":"Chiari","year":"2025","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/jamaoncol.2026.0020","article-title":"First-Line Tislelizumab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Cancer: Three-Year Follow-Up of the Phase 3 RATIONALE-309 Randomized Clinical Trial","volume":"12","author":"Yang","year":"2026","journal-title":"JAMA Oncol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/S1470-2045(21)00302-8","article-title":"Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): A multicentre, randomised, double-blind, phase 3 trial","volume":"22","author":"Yang","year":"2021","journal-title":"Lancet Oncol."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/5\/764\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T04:24:32Z","timestamp":1779164672000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/5\/764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,2]]},"references-count":150,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["life16050764"],"URL":"https:\/\/doi.org\/10.3390\/life16050764","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,2]]}}}